Eli Lilly and Company (LLY)
Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 66.2502
- Book/Share 26.5925
- PB 40.4258
- Debt/Equity 1.7865
- CurrentRatio 1.5463
- ROIC 0.279
- MktCap 963348484992.0
- FreeCF/Share 10.0576
- PFCF 106.7931
- PE 52.2408
- Debt/Assets 0.3698
- DivYield 0.0056
- ROE 1.0226
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | LLY | Scotiabank | -- | Sector Outperform | -- | $1165 | Nov. 13, 2025 |
| Upgrade | LLY | Leerink Partners | Market Perform | Outperform | -- | $1104 | Nov. 10, 2025 |
| Reiterated | LLY | BMO Capital Markets | -- | Outperform | $840 | $930 | Oct. 20, 2025 |
| Upgrade | LLY | Erste Group | Hold | Buy | -- | -- | Oct. 14, 2025 |
| Downgrade | LLY | Berenberg | Buy | Hold | -- | $830 | Sept. 17, 2025 |
| Upgrade | LLY | HSBC Securities | Reduce | Hold | -- | $700 | Aug. 27, 2025 |
| Downgrade | LLY | Daiwa Securities | Outperform | Neutral | -- | $700 | Aug. 18, 2025 |
| Downgrade | LLY | Leerink Partners | Outperform | Market Perform | -- | $715 | Aug. 7, 2025 |
| Downgrade | LLY | Erste Group | Buy | Hold | -- | -- | June 5, 2025 |
| Downgrade | LLY | HSBC Securities | Buy | Reduce | $1150 | $700 | April 28, 2025 |
News
PFE vs. LLY: Which Stock Is the Better Value Option?
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Eli Lilly (LLY). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Trade Tracker: Stephanie Link sells Eli Lilly and buys more Intuitive Surgical
Published: May 12, 2025 by: CNBC Television
Sentiment: Neutral
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.
Read More
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Read More
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy in obesity drug trial
Published: May 12, 2025 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co (NYSE:LLY)'s weight loss drug Zepbound (tirzepatide) has shown superior results compared to Novo Nordisk (NYSE:NVO)'s Wegovy (semaglutide) in a direct clinical trial, marking the first head-to-head comparison between the two leading obesity treatments. In the 72-week SURMOUNT-5 trial, participants on Zepbound lost an average of about 50 pounds (22.8 kg), equating to approximately 20.2% of their body weight.
Read More
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Negative
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.
Read More
Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival's Wegovy
Published: May 12, 2025 by: WSJ
Sentiment: Positive
The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk's Wegovy in a head-to-head study of the two drugs.
Read More
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (May 2025)
Published: May 12, 2025 by: 24/7 Wall Street
Sentiment: Positive
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%.
Read More
Pfizer, Eli Lilly, Other Pharma Stocks Fall as Trump Targets Lower Drug Prices
Published: May 12, 2025 by: Barrons
Sentiment: Negative
Trump said he would lower the cost of medicines for Americans by between 30% and 80%.
Read More
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial
Published: May 11, 2025 by: Reuters
Sentiment: Positive
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.
Read More
Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine
Published: May 11, 2025 by: PRNewsWire
Sentiment: Neutral
Participants achieved an average weight loss of 20.2% with Zepbound vs. 13.7% with Wegovy In key secondary endpoints, Zepbound was superior to Wegovy across all weight reduction targets and waist circumference reduction INDIANAPOLIS , May 11, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound (tirzepatide), a dual GIP and GLP-1 receptor agonist, compared to Wegovy (semaglutide), a mono GLP-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes.
Read More
Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
Published: May 09, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS and WEST LAFAYETTE, Ind. , May 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly's planned investment of up to $250 million in the collaboration over the next eight years.
Read More
Top Stock Movers Now: AB InBev, Molson Coors, Eli Lilly, and More
Published: May 08, 2025 by: Investopedia
Sentiment: Neutral
U.S. equities advanced at midday as President Donald Trump announced a new trade deal with the United Kingdom. The Dow Jones Industrial Average, S&P 500, and Nasdaq all rose.
Read More
Lilly announces transitions in executive leadership
Published: May 08, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , May 8, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced executive leadership transitions that will further enhance the company's ability to drive sustained, long-term growth and ensure that its medicines continue to reach millions of people worldwide. Lilly has experienced significant growth over the past several years, particularly in the U.S. and cardiometabolic health businesses.
Read More
US judge sides with FDA's removal of Lilly's weight loss drug from shortage list
Published: May 07, 2025 by: Reuters
Sentiment: Negative
A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly's blockbuster weight loss and diabetes drugs Zepbound and Mounjaro off a list of medicines in short supply, a ruling that could dash patients' hopes of regaining access to cheaper copies of the popular therapies.
Read More
Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
Published: May 07, 2025 by: CNBC
Sentiment: Neutral
Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.
Read More
Eli Lilly Being Investigated on Behalf of Eli Lilly and Company Investors. Contact Levi & Korsinsky For Details
Published: May 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Eli Lilly and Company ("Eli Lilly") (NYSE:LLY) concerning possible violations of federal securities laws. On May 1, 2025, Eli Lilly issued a press release reporting first quarter 2025 results and reaffirming guidance.
Read More
Pharma sector still investable, faces added headwinds, says BMO's Siegerman
Published: May 06, 2025 by: CNBC Television
Sentiment: Neutral
Evan Siegerman, BMO Capital Markets, joins 'Fast Money' to talk new headwinds facing the pharma sector.
Read More
Eli Lilly Stock Slips on Outlook. Is It Time to Buy the Dip?
Published: May 06, 2025 by: The Motley Fool
Sentiment: Negative
Shares of Eli Lilly (LLY -2.90%) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. However, the guidance reduction stems from an up-front payment it made to acquire Scorpion Therapeutics' STX-478 program to treat breast cancer.
Read More
LLY ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Eli Lilly and Company investment
Published: May 06, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Eli Lilly and Company ("Eli Lilly") (NYSE:LLY) concerning possible violations of federal securities laws. On May 1, 2025, Eli Lilly issued a press release reporting first quarter 2025 results and reaffirming guidance.
Read More
Lilly declares second-quarter 2025 dividend
Published: May 05, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , May 5, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the second quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on June 10, 2025, to shareholders of record at the close of business on May 16, 2025.
Read More
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Read More
An Investigation Has Commenced on Behalf of Eli Lilly and Company Shareholders. Contact Levi & Korsinsky to Discuss your LLY Losses
Published: May 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Eli Lilly and Company ("Eli Lilly") (NYSE:LLY) concerning possible violations of federal securities laws. On May 1, 2025, Eli Lilly issued a press release reporting first quarter 2025 results and reaffirming guidance.
Read More
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
Published: May 02, 2025 by: The Motley Fool
Sentiment: Positive
Positive jobs news and positive rumors out of China are lifting stock markets today, as the U.S. Labor Department reports adjusted nonfarm payrolls grew by 177,000 jobs in April, and CNBC reports that China may be "evaluating the possibility of starting trade negotiations" that could abbreviate a trade war with the U.S.
Read More
Eli Lilly's Stock Selloff Is Overdone, Analysts Say. Here's Why.
Published: May 02, 2025 by: Barrons
Sentiment: Positive
Analysts were rushing to reiterate their conviction in the stock following Thursday's blow to Zepbound and Lilly shares.
Read More
Eli Lilly and Company (LLY) Q1 2025 Earnings Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly and Company (NYSE:LLY ) Q1 2025 Results Conference Call May 1, 2025 10:00 AM ET Company Participants Mike Czapar - Senior Vice President of Investor Relations Dave Ricks - Chair and CEO Lucas Montarce - Chief Financial Officer Dan Skovronsky - Chief Scientific Officer & President of Lilly Immunology Patrik Jonsson - President of Lilly Cardiometabolic Health & Lilly USA Anne White - President of Lilly Neuroscience Ilya Yuffa - President of Lilly International Jake Van Naarden - President of Lilly Oncology Marc Kemen - Investor Relations Wes Taul - Investor Relations Wai Wong - Investor Relations Conference …
Read More
CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Negative
Eli Lilly and Company's stock fell over 11% after CVS Caremark excluded Lilly's obesity drug Zepbound from its standard commercial formularies starting July 1, 2025. The market overreacted to CVS's exclusion, creating a temporary mispricing in Lilly's stock, presenting a potential buying opportunity. Despite CVS's exclusion, Zepbound still has broad market access through other PBMs and regional health plans, ensuring continued sales growth.
Read More
LLY's Q1 Earnings Miss, Mounjaro & Zepbound Drive Sales, Stock Down
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat estimates.
Read More
Why Eli Lilly Stock Is Sinking Today
Published: May 01, 2025 by: The Motley Fool
Sentiment: Negative
Shares of Eli Lilly (LLY -10.79%) are sliding on Thursday. The stock lost 8.3% as of 12:21 p.m.
Read More
Initial Claims More Than Expectations
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
Initial Claims More Than Expectations.
Read More
Eli Lilly CEO David Ricks on pricing of the new weight loss pill if approved
Published: May 01, 2025 by: CNBC Television
Sentiment: Neutral
Eli Lilly chairman and CEO David Ricks discusses the status of the company's weight loss drug pill.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000